Who we are
Gadea Pharmaceutical Group is an independent Spanish group of affiliated companies dedicated to the technical development services, production and marketing of APIs. This group includes Ragactives, started in 1991 as an APIs process development company; Crystal Pharma, founded in 1996, dedicating its activity to the production and marketing of steroids; and Solea, incorporated in 2005, a chemical plant located in Malta. Gadea Pharmaceutical Group, as the mother company, is encompassing the activity of the affiliated companies.
Gadea is managed and run by a team of professional chemists which have great experience and expertise in this type of products. More than 60% of our employees are qualified chemists and many of them hold doctorate degrees.
ABOUT US
Business strategy
Based on the development and manufacturing of high quality active pharmaceutical ingredients for the most demanding regulated markets. From R&D to sterile quality, including Intelectual Property, customers are essential part of the business.
Manufacturing
Four multipurpose synthesis plants, and one sterile facility for commercial production with capacity ranges from milligrams for clinical studies, to multi-kilograms.
High quality products manufactured under strict cGMP conditions
Thorough control of all process steps, including wastes and emissions.
Technological development services
Well documented DMFs according to FDA and EU requirements.
The company's areas of interest, always associated with steroids, include: Chemical Synthesis of APIs including high-potency progestins, Research and Development and Sterile Crystallization.
Ragactives started its activities in the early nineties providing customers
the opportunity to outsource their development needs.
Our current product portfolio is a testament to our success in the development
of innovative and economically viable synthesis routes for the production
of these products.
R&D developed and transferred by Ragactives, Solea Pharma production unit, located in Malta, offers an attractive patent position and a well established Quality System.
Main goal is to provide an incentive for generic manufacturers, to file certifications challenging patents that may be invalid, non infringed by the product which is subject of the ANDA.
